Blueshot Blog
Expert guides on GLP-1 medications, weight management, and healthy living
Medication GuideYour Brain on GLP-1: Why Food Noise Goes Silent
GLP-1 drugs rewire brain circuits that keep you thinking about food. The neuroscience of 'food noise,' why alcohol cravings fade too, and what happens when you stop.
Medication GuideGLP-1 Loose Skin: What's Real, What Helps, and When to Talk to a Surgeon
Lose 15-22% of your body weight on a GLP-1 and your skin can't keep up. What works for preventing loose skin — and what to do when it's already there.
Medication GuideVitamin Gaps on GLP-1s: Which Nutrients You're Probably Missing
Eating 40% less means absorbing 40% fewer vitamins. Vitamin D, B12, iron, calcium, and zinc are the biggest gaps on Wegovy, Mounjaro, and Ozempic — here's the testing and supplement plan.
Medication GuideGLP-1 Nausea, Bloating, and Sulfur Burps: What Helps and When to Worry
Nausea hits 44% on Wegovy and 33% on Mounjaro. Sulfur burps, constipation, and bloating follow close behind. A meal-by-meal, hour-by-hour playbook for the rough days.
Medication GuideGLP-1 Summer Travel Storage: Drug-by-Drug Cold Chain Guide (2026)
Car trunks hit 70°C in 30 minutes. Mounjaro's out-of-fridge window is just 21 days. Drug-by-drug packing plan for summer flights and road trips.
Medication GuideOzempic vs Wegovy: Same Drug, Different Rules
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. So why do they cost different amounts, and which one should you ask about?
Medication GuideSwitching GLP-1 Meds: Dose Maps and Real Talk
Thinking about switching from Wegovy to Mounjaro — or from injections to the new pill? Here's how dose mapping actually works and what the transition feels like.
Medication GuideGLP-1 and Bone Loss: What Rapid Weight Loss Does to Your Skeleton (2026)
Lose 15% of your body weight and you'll lose some bone too. DXA data from STEP and SURMOUNT show how much — and what actually protects you.
NewsGLP-1 Drugs Just Became the World's Best-Selling Drug Class (2026)
Novo Nordisk and Eli Lilly's GLP-1 revenue hit $60B+ annualized in Q1 2026, overtaking oncology. What record sales mean for pricing, supply, and access.
Medication GuideGLP-1 and Pancreatitis: Separating Real Risk from Internet Panic (2026)
Pancreatitis is on every GLP-1 label. Clinical trial rates are under 0.5%. Here's what STEP, SURMOUNT, and SELECT actually show.
Medication GuideGLP-1 and Thyroid Cancer: What the Black Box Warning Actually Means (2026)
Every GLP-1 drug carries a boxed warning about thyroid cancer. But 145,000-patient cohort data and 15 years of surveillance say the human risk is near zero. Here's the evidence.
Medication GuideGLP-1 and Gallbladder Problems: What the Data Actually Shows (2026)
Gallstones and cholecystitis are a real risk on semaglutide and tirzepatide — about 2–3% in trials vs 1% on placebo. Here's why it happens, who's most at risk, and what to watch for.
Medication GuideYour Stomach on a GLP-1: Gastroparesis, Nausea, and What the Evidence Actually Says
Gastroparesis fears, sulfur burps, nausea that makes you question everything — here's what the clinical data says about GLP-1s and your gut, and when to worry.
Medication GuideGLP-1 Long-Term Safety: What the Trial Data Shows (2026)
LEADER, REWIND, SELECT, SOUL, FLOW — 50,000+ patients, up to 5.4 years. What the long-term data says about thyroid, heart, kidneys, gallbladder, and more.
Medication GuideEvery Pill You Take With a GLP-1 — What Actually Interacts and What Doesn't
You're on Wegovy or Mounjaro and you take other meds too. Here's what the prescribing labels, clinical data, and your pharmacist actually worry about.
Medication GuideGLP-1 Weight Loss Plateau: Why You Stalled and What Actually Works
Most people hit a wall at months 3-6 on semaglutide or tirzepatide. The plateau isn't failure — it's biology. Here's what the STEP and SURMOUNT data says about breaking through.
Medication GuideYour Kidneys on GLP-1: What the FLOW Trial Found (and What It Means for You)
The FLOW trial stopped early because semaglutide cut major kidney events by 24%. If you have type 2 diabetes and CKD, here's what the 2024 data means for your kidneys.
NewsOral Semaglutide Hits 400K Users — Where the GLP-1 Pill Stands Globally
Four months after US launch, oral semaglutide for obesity has 400,000 patients on it. Here's which markets have it, which are next, and what the real-world data says so far.